Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMPE NASDAQ:EFTR NASDAQ:HSTO NASDAQ:ONCSQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.01+9,900.0%$0.02$0.00▼$0.13$11K4.76734 shs7,588 shsEFTReFFECTOR Therapeutics$0.00$0.00$0.00▼$0.10$1K13,102 shs4 shsHSTOHistogen$0.04+11,600.0%$0.02$0.05▼$0.55$150K1.1910,369 shs96 shsONCSQOncoSec Medical$0.00$0.00▼$0.00$1K-19.7204 shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals+9,900.00%+270.37%-91.39%+376.19%-88.89%EFTReFFECTOR Therapeutics0.00%0.00%-33.33%0.00%-99.67%HSTOHistogen+11,600.00%+11,600.00%+98.31%+21.03%-83.29%ONCSQOncoSec Medical0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AEFTReFFECTOR Therapeutics0.0757 of 5 stars0.02.00.00.00.60.80.0HSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/AONCSQOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPEAmpio Pharmaceuticals 0.00N/AN/AN/AEFTReFFECTOR Therapeutics 0.00N/AN/AN/AHSTOHistogen 0.00N/AN/AN/AONCSQOncoSec Medical 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/A($1.94) per shareN/AHSTOHistogen$19K7.89N/AN/A$3.13 per share0.01ONCSQOncoSec MedicalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/A∞N/AN/AN/AN/AN/AEFTReFFECTOR Therapeutics-$35.81M-$13.08N/A∞N/AN/AN/AN/A7/28/2025 (Estimated)HSTOHistogen-$10.62M-$2.81N/A∞N/AN/AN/AN/AN/AONCSQOncoSec Medical-$34.18MN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/AONCSQOncoSec MedicalN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPEAmpio Pharmaceuticals5.73%EFTReFFECTOR Therapeutics57.67%HSTOHistogenN/AONCSQOncoSec MedicalN/AInsider OwnershipCompanyInsider OwnershipAMPEAmpio Pharmaceuticals3.30%EFTReFFECTOR Therapeutics4.70%HSTOHistogen3.30%ONCSQOncoSec Medical1.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataEFTReFFECTOR Therapeutics104.70 million4.48 millionNo DataHSTOHistogen204.27 millionN/ANot OptionableONCSQOncoSec Medical405.96 million5.88 millionNot OptionableONCSQ, AMPE, EFTR, and HSTO HeadlinesRecent News About These CompaniesOncoSec Announces Closing of the CGP/Sirtex TransactionJune 10, 2025 | businesswire.comOncoSec Medical (OTC:ONCSQ) Stock, Short Interest ReportJune 1, 2025 | benzinga.comOncoSec Medical Incorporated (ONCSQ)December 5, 2024 | nz.finance.yahoo.comClinical decision-making insights for haem/oncsSeptember 14, 2024 | pharmaphorum.comPOncoSec Medical Inc ONCSQNovember 8, 2023 | morningstar.comMONCSQ OncoSec Medical IncorporatedAugust 18, 2023 | seekingalpha.comONMA.BE - OncoSec Medical IncJuly 17, 2023 | finance.yahoo.comOncoSec Medical Inc (ONCSQ)July 14, 2023 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCSQ, AMPE, EFTR, and HSTO Company DescriptionsAmpio Pharmaceuticals NYSE:AMPE$0.01 +0.01 (+9,900.00%) As of 07/15/2025 11:08 AM EasternAmpio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.eFFECTOR Therapeutics NASDAQ:EFTR$0.0002 0.00 (0.00%) As of 07/14/2025eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.Histogen NASDAQ:HSTO$0.04 +0.03 (+11,600.00%) As of 07/14/2025Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.OncoSec Medical NASDAQ:ONCSQOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. On June 14, 2023, OncoSec Medical Incorporated filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
